5/21/2003 4:46:40 PM ET


    Global Path Appoints New Chairman & CEO and Announces Name Change to Swiss Medica
      
    TORONTO, and MUNICH, Germany, May 21, 2003 /PRNewswire-FirstCall via COMTEX/ --
    Global Path Inc. (OTC Bulletin Board: GBPI) is pleased to announce the appointment of a new Chairman, CEO
    and CFO: Mr. Raghu Kilambi. Global Path is also pleased to announce that it is changing its name to Swiss
    Medica Inc., to reflect its new single focus on biosciences. As part of the name change process, Swiss Medica
    Inc. will be issued a new stock symbol and CUSIP number. Global Path has filed a preliminary information
    statement Schedule 14C with the S.E.C. concerning the name change, and will be mailing information on the
    name change to shareholders shortly. The name and symbol changes are expected to be effective on June 20,
    2003. Further information on the name change, symbol change and new CUSIP number will be disclosed to
    shareholders in a press release in the next several weeks.

    Effective immediately, Mr. Raghu Kilambi will assume the role of Chairman, CEO and CFO of Swiss Medica.
    Kilambi is a seasoned new economy executive with over sixteen years of broad business experience in building
    businesses and creating shareholder value. Kilambi's experience includes corporate finance, strategic
    acquisitions, business development, operations management, merchant banking, corporate restructuring, and
    financial reporting/compliance.

    Kilambi is a principal of Rubicon Investment Group; a Toronto-based merchant bank focused on private equity
    buyouts and active public market investments. Since 2001, Rubicon has made several successful investments in
    the information technology services and natural resources fields that have generated significant return on
    investments for Rubicon and its investors. Prior to Rubicon, Kilambi was Co-Founder and CFO of FutureLink
    Corp., an application service provider that had $140 million in revenue and a peak market capitalization of US$2
    billion. FutureLink was a Forbes ASAP Top 25 Ramp Champ in 1999 and 2000. Kilambi led FutureLink's growth
    strategy, acquiring 8 companies and completing US$225 million of financing between 1998 and 2000.
    Previously, Kilambi was a merchant banker focused on funding growth companies, such as C2B Technologies
    (acquired by Inktomi/Yahoo). Kilambi earned a Bachelor of Commerce and a Graduate Diploma in Public
    Accounting from McGill University in Montreal and is a Chartered Accountant.

    'Raghu Kilambi was the perfect choice to lead Swiss Medica into the future,'states Robert Kubbernus, the
    departing Chairman, CEO and CFO. 'With our recently announced bioscience acquisitions, I knew that the
    company needed to be guided by an executive, such as Raghu, who understands how to rapidly grow new
    economy businesses on a global scale, while maintaining the strict financial controls necessary to meet
    corporate objectives and shareholder expectations. As our bioscience product suite has incredible potential for
    significant revenue growth, we needed an experienced executive team to realize this potential. As a large
    shareholder, I believe my investment in Swiss Medica is in very good hands with Kilambi at the helm,'concludes
    Kubbernus.

    'I was pleased when Robert Kubbernus decided to singly focus Global Path on the high growth bioscience field
    and rename the company Swiss Medica. Swiss Medica's bioscience products are clearly one of the most
    attractive growth opportunities I have seen in my career,'states Raghu Kilambi, new Chairman and CEO of Swiss
    Medica Inc.

    'I am very excited to lead Swiss Medica as we build a leading bioscience company. Our bioscience products have
    world-class endorsements and are in markets with revenue potentials greater than any of the new economy
    companies I have seen during my career. I look forward to the opportunity and challenge of building a strong
    team and commercializing these high potential products,' concludes Kilambi.

    About Swiss Medica Inc.

    Swiss Medica Inc. is focused on acquiring over-the-counter bioscience products with demonstrated competitive
    advantages and increasing their revenues by focused sales and marketing efforts in selected distribution
    channels including direct sales, direct response, and e-commerce. Swiss Medica's mission is to be a world
    leader in the acquisition and commercialization of life enhancing bioscience products that improve quality of lives.

    Forward-looking statements in this news release are made pursuant to the 'Safe Harbor'provisions of the United
    States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Global Path's services, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Global Path's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.



    Dave Jones: 705 495 0022
    djones@swissmedica.com